Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds

Swiss clinical-stage biotech Windward Bio Group AG, which is developing ultra-long-acting antibodies for respiratory and dermatologic diseases, priced its initial public offering on Nov. 12, 2026. It is selling 10,294,117 common shares at $17.00 each and has granted underwriters a 30-day option for up to 1,544,117 more. Expected gross proceeds of $225.0 million include a concurrent private placement and exclude the underwriters' option.

12 Nov 2026 · Windward Bio Group AG · Company news

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →

Financing

Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds

IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M

Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597

Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants

Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities

Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq

Tenon Medical Q3 2026 revenue up 22% to $1.4M; convertible notes repaid after $15.6M raised